Mitsubishi joins Eisai, 3SBio's bet on multispecific antibodies, upping Numab's Series B haul to $23M+
Following a busy year of dealmaking, Swiss antibody shop Numab has closed a Series B at CHF22 million ($23.87 million) to double down on its multispecific molecules for immuno-oncology and grow its team.
The bulk of the cash comes from familiar names. China’s 3SBio already committed CHF15 million ($15.2 million) when its subsidiary Sunshine Guojian signed onto a regional development and commercialization deal late last year. Eisai, which is in for a discovery pact, chipped in alongside Mitsubishi UFJ Capital and Daniel Vasella — the former CEO of Novartis and a Numab board member.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.